ClinicalTrials.gg
TerminatedNCT03367819Updated May 16, 2022Results posted

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

A Phase 1/2 interventional study of Isatuximab SAR650984 and Cemiplimab REGN2810 in Prostate Cancer and Non-small Cell Lung Cancer, sponsored by Sanofi. Terminated at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-16.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was stopped after interim analysis indicated that overall result was not sufficient to satisfy per-protocol criteria to move forward in metastatic, castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) cohorts.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Prostatic Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Prostatic Neoplasms · Sanofi.

Enrollment
19th of 31
44 · median 54
Started
2018
the only one that year
Phase 1/2
2 of 34
none open now
Registered
34th of 34
by date

Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 1/2, and was the 34th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 34 studies in Prostatic Neoplasms by Sanofi is open now. The open studies under Prostatic Neoplasms, anywhere →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies in Prostatic Neoplasms by Sanofi as a file.
02

Study summary

Primary Objectives:

  • To characterize the safety and tolerability of isatuximab in combination with REGN2810 in participants with metastatic, castration-resistant prostate cancer (mCRPC) who were naïve to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)-containing therapy, or non-small cell lung cancer (NSCLC) who progressed on anti-PD-1/PD-L1-containing therapy, and to confirm the recommended Phase 2 dose (RP2D).
  • To assess the response rate of isatuximab in combination with REGN2810 in participants with either mCRPC who were anti-PD-1/PD-L1 therapy naive, or NSCLC who progressed on anti-PD-1/PD-L1 therapy, or of isatuximab as single agent in participants with mCRPC.

Secondary Objectives:

  • To evaluate the safety of the combination of isatuximab with REGN2810 or isatuximab monotherapy.
  • To evaluate the immunogenicity of isatuximab and REGN2810.
  • To characterize the pharmacokinetic (PK) profile of isatuximab single agent or in combination with REGN2810, and to characterize the PK of REGN2810 in combination with isatuximab.
  • To assess overall efficacy of isatuximab in combination with REGN2810 or as a single agent.
Read the detailed description

The total study duration per participant was up to 28 months including an up to 28 days screening period, an up to 24 months treatment period, and a 3 months safety follow up period.

03

Conditions studied

  • Prostate Cancer
  • Non-small Cell Lung Cancer

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must had a known diagnosis of either castration-resistant prostate cancer (mCRPC) or non-small cell lung cancer (NSCLC) with evidence of .
  • Failure of, inability to, or refusal to receive standard of care.
  • Greater than or equal to (>=) 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to isatuximab or participation in clinical studies with isatuximab.
  • For participants with mCRPC, prior exposure to any agent (approved or ) that blocks the /PD-L1 pathway.
  • Evidence of other immune related disease /conditions.
  • History of non-infectious pneumonitis requiring or current pneumonitis; history of the thoracic radiation.
  • Had received a live-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus were permitted.
  • Prior solid organ or hematologic transplant.
  • performance status (PS) >=2.
  • Poor bone marrow reserve.
  • Poor organ function.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Phase 1: mCRPC/NSCLC

    Isatuximab dose 1 and REGN2810 predefined dose

    Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810

  • Experimental
    Cohort A-1: mCRPC, isatuximab and REGN2810 combination

    Participants with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose

    Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810

  • Experimental
    Cohort A-2: mCRPC, isatuximab monotherapy

    Participants with mCRPC will be given isatuximab dose 2

    Drug: Isatuximab SAR650984

  • Experimental
    Phase 2 Cohort B: NSCLC

    Participants with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose

    Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810

  • Experimental
    Possibly Phase 2 Cohort C: mCRPC

    Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in participants with mCRPC

    Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810

  • Experimental
    Possibly Phase 2 Cohort D: NSCLC

    Isatuximab dose 3 will be given in combination with REGN2810 predefined dose

    Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810

Interventions

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Sarclisa

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)

    DLTs: adverse events occurring during 1st treatment cycle, unless due to disease progression/to cause obviously unrelated to investigational medicinal product (IMP) which included:hematological abnormalities: Grade(G) 4 neutropenia(N) for 7/more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia with clinically significant bleeding. Non-hematological abnormalities: G4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days (except G3 fatigue, allergic reaction/hypersensitivity attributed to isatuximab or REGN2810 and G3 or G4 clinically non-significant laboratory abnormality), delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other toxicity that Investigator and Sponsor deemed to be dose-limiting, regardless of grade, was also considered as DLT.

    Time frame: Cycle 1 (21 days)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs.

    Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

  3. Number of Participants With Laboratory Abnormalities: Hematological Parameters

    Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased and neutrophil count decreased. Abnormality criteria was based on National Cancer Institute Common Terminology Criteria for Adverse Event version 4.03 (NCI-CTCAE v 4.03), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

    Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

  4. Number of Participants With Laboratory Abnormalities: Electrolytes

    Abnormal electrolytes parameters assessed were hyponatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia and hyperglycemia. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

    Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

  5. Number of Participants With Laboratory Abnormalities: Renal Parameters

    Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: \>=60 - less than (\<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2), \>=30 - \<60 mL/min/1.73m\^2, \>=15 - \<30 mL/min/1.73m\^2 and \<15 mL/min/1.73m\^2. Creatinine increased and hyperuricemia abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. For all these 3 parameters, only those categories in which at least 1 participant had data were reported.

    Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

  6. Number of Participants With Laboratory Abnormalities: Liver Function Parameters

    Abnormal liver function parameters assessed were aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

    Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

  7. Overall Response Rate (ORR): Percentage of Participants With Overall Response

    For participants with mCRPC, response was defined as achieving complete response (CR) or partial response (PR) as best overall response (BOR) for soft tissue assessed and confirmed by the Investigators and/or a prostate-specific antigen (PSA) decline of \>=50 percent (%) from Baseline that was subsequently confirmed per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. For participants with NSCLC, ORR was defined as the percentage of participants with CR or PR as BOR according to RECIST 1.1. criteria. Per RECIST 1.1. criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \<10 millimeters (mm) and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.

    Time frame: From the date of randomization to the date of first documentation of progression or death due to any cause, whichever occurred first (maximum duration: up to 2 years)

Secondary outcomes

  1. Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab, Post Treatment

    ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

    Time frame: From Baseline up to 2 years

  2. Number of Participants With Anti-drug Antibodies (ADA) Response Against REGN2810, Post Treatment

    ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

    Time frame: From Baseline up to 2 years

  3. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab

    Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for isatuximab for participants with mCRPC and NSCLC.

    Time frame: At start of infusion (SOI), before actual end of infusion (EOI), EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

  4. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of REGN2810

    Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for REGN2810 for participants with mCRPC and NSCLC.

    Time frame: At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1

  5. Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours (AUC0-168 hr) After the First Administration of Isatuximab

    AUC0-168 hr was defined as the area under the plasma concentration-time curve from time zero to 168h and was calculated using the trapezoidal method over the dosing interval (i.e., 7 days) for isatuximab alone.

    Time frame: At SOI, before actual EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

  6. Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 504 Hours (AUC0-504 hr) After the First Administration of REGN2810

    AUC0-504 hr was defined as the area under the plasma concentration-time curve from time zero to 504h and was calculated using the trapezoidal method over the dosing interval (i.e., 21 days) for REGN2810 alone.

    Time frame: At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, 336 hours and 504 hours post-dose on Day 1 of Cycle 1

  7. Best Percent-change From Baseline in Tumor Burden

    Tumor burden change was defined as the best percent-change from Baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.

    Time frame: Up to 2 years

  8. Duration of Response (DOR)

    DOR: defined as time (in months) from date of first response (PR or CR in radiographic objective response, or PSA decline \>=50% for participants with mCRPC) that was subsequently confirmed to the date of first disease progression (PD) or death, whichever occurred first. PD included radiographic disease progression or unequivocal clinical progression. RECIST 1.1 criteria was used to assess radiographic PD in participants with NSCLC and PCWG3 criteria for participants with mCRPC. Per RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to \<10 mm and PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (Baseline sum if that was smallest), sum with an absolute increase of at least 5 mm and appearance of 1 or more new lesions.

    Time frame: From the date of first response until disease progression or death, whichever occurred first (maximum duration: up to 2 years)

  9. Progression-free Survival (PFS)

    For mCRPC participants, PFS was defined as the time (in months) from first study treatment administration to the date of first documented disease progression or the date of death from any cause, whichever occurred first. Disease progression included radiographic disease progression (per PCWG3 criteria) or unequivocal clinical progression. For NSCLC participants, PFS was defined as the time from first study treatment administration to the date of first documented radiographic progression (PD) (per RECIST 1.1) or the date of death from any cause, whichever occurred first. Per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the Baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered as progression. Analysis was performed using Kaplan-Meier method.

    Time frame: From the date of the first study treatment administration to the date of first documented disease progression or death of any cause, whichever occurred first (maximum duration: up to 2 years)

  10. Percentage of Participants With Disease Control (DC) >=6 Months

    Disease control: defined as percentage of participants with confirmed CR/PR/stable disease (SD), as assessed by Investigator PCWG3 modified RECIST 1.1 criteria relative to total number of participants in analysis population. Per PCWG3 modified RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to \<10 mm, PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference Baseline sum diameters and SD: neither sufficient shrinkage from the Baseline to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study, sum with an absolute increase of diameter of at least 5 mm and appearance of 1 or more new lesions.

    Time frame: From the date of first response to the date of first documented disease progression or death (due to any cause) (maximum duration: up to 2 years)

07

Results

Posted May 16, 2022
Limitations and caveats
The study was terminated after the interim analysis of the primary endpoint. Few planned outcome measures per-protocol were not analyzed because overall efficacy results were not sufficient at the time of interim analyses of both the cohorts.

Participant flow

Study was conducted at 16 active sites in 5 countries. A total of 44 participants were enrolled between 04 January 2018 and 18 January 2019 and received isatuximab in combination with REGN2810.

Participant flow — Overall Study
MilestonemCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Started2420
Completed01
Not completed2419
Withdrew: Adverse event44
Withdrew: Progressive disease1513
Withdrew: Withdrawal by subject10
Withdrew: Other42

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

DLTs: adverse events occurring during 1st treatment cycle, unless due to disease progression/to cause obviously unrelated to investigational medicinal product (IMP) which included:hematological abnormalities: Grade(G) 4 neutropenia(N) for 7/more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia with clinically significant bleeding. Non-hematological abnormalities: G4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days (except G3 fatigue, allergic reaction/hypersensitivity attributed to isatuximab or REGN2810 and G3 or G4 clinically non-significant laboratory abnormality), delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other toxicity that Investigator and Sponsor deemed to be dose-limiting, regardless of grade, was also considered as DLT.

Time frame:
Cycle 1 (21 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Number of Participants With Dose Limiting Toxicities (DLTs)00
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs.

Time frame:
From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Any TEAEs2420
Any TESAEs1114
PrimaryNumber of Participants With Laboratory Abnormalities: Hematological Parameters

Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased and neutrophil count decreased. Abnormality criteria was based on National Cancer Institute Common Terminology Criteria for Adverse Event version 4.03 (NCI-CTCAE v 4.03), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

Time frame:
From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities: Hematological Parameters
ParticipantsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Anemia: Grade 1109
Anemia: Grade 292
Anemia: Grade 343
WBC decreased: Grade 182
WBC decreased: Grade 250
Platelet count decreased: Grade 151
Platelet count decreased: Grade 220
Platelet count decreased: Grade 310
Lymphocyte count decreased: Grade 147
Lymphocyte count decreased: Grade 284
Lymphocyte count decreased: Grade 352
Lymphocyte count decreased: Grade 410
Neutrophil count decreased: Grade 132
Neutrophil count decreased: Grade 220
PrimaryNumber of Participants With Laboratory Abnormalities: Electrolytes

Abnormal electrolytes parameters assessed were hyponatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia and hyperglycemia. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

Time frame:
From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities: Electrolytes
ParticipantsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Hyponatremia: Grade 188
Hypokalemia: Grade 132
Hyperkalemia: Grade 132
Hypocalcemia: Grade 163
Hypocalcemia: Grade 210
Hypercalcemia: Grade 111
Hypercalcemia: Grade 201
Hypoalbuminemia: Grade 162
Hypoalbuminemia: Grade 213
Hypoalbuminemia: Grade 301
Hyperglycemia: Grade 1113
Hyperglycemia: Grade 255
Hyperglycemia: Grade 310
Hypoglycemia: Grade 101
Hypoglycemia: Grade 201
PrimaryNumber of Participants With Laboratory Abnormalities: Renal Parameters

Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: \>=60 - less than (\<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2), \>=30 - \<60 mL/min/1.73m\^2, \>=15 - \<30 mL/min/1.73m\^2 and \<15 mL/min/1.73m\^2. Creatinine increased and hyperuricemia abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. For all these 3 parameters, only those categories in which at least 1 participant had data were reported.

Time frame:
From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities: Renal Parameters
ParticipantsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
CrCl: >=60 - <90 mL/min/1.73m^2613
CrCl: >=30 - <60 mL/min/1.73m^2112
Creatinine increased: Grade 11815
Hyperuricemia: Grade 323
Hyperuricemia: Grade 410
PrimaryNumber of Participants With Laboratory Abnormalities: Liver Function Parameters

Abnormal liver function parameters assessed were aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

Time frame:
From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities: Liver Function Parameters
ParticipantsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
AST increased: Grade 162
AST increased: Grade 210
ALT increased: Grade 120
ALP increased: Grade 139
ALP increased: Grade 240
ALP increased: Grade 360
BB increased: Grade 121
PrimaryOverall Response Rate (ORR): Percentage of Participants With Overall Response

For participants with mCRPC, response was defined as achieving complete response (CR) or partial response (PR) as best overall response (BOR) for soft tissue assessed and confirmed by the Investigators and/or a prostate-specific antigen (PSA) decline of \>=50 percent (%) from Baseline that was subsequently confirmed per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. For participants with NSCLC, ORR was defined as the percentage of participants with CR or PR as BOR according to RECIST 1.1. criteria. Per RECIST 1.1. criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \<10 millimeters (mm) and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.

Time frame:
From the date of randomization to the date of first documentation of progression or death due to any cause, whichever occurred first (maximum duration: up to 2 years)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR): Percentage of Participants With Overall Response
percentage of participantsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Overall Response Rate (ORR): Percentage of Participants With Overall Response4.2 (0.2 to 18.3)0 (0.0 to 13.9)
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab, Post Treatment

ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

Time frame:
From Baseline up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab, Post Treatment
ParticipantsmCRPC + NSCLC : Isatuximab + REGN2810
Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab, Post Treatment0
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) Response Against REGN2810, Post Treatment

ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

Time frame:
From Baseline up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA) Response Against REGN2810, Post Treatment
ParticipantsmCRPC + NSCLC : Isatuximab + REGN2810
Number of Participants With Anti-drug Antibodies (ADA) Response Against REGN2810, Post Treatment1
SecondaryPharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab

Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for isatuximab for participants with mCRPC and NSCLC.

Time frame:
At start of infusion (SOI), before actual end of infusion (EOI), EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · micrograms per milliliter
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab
micrograms per millilitermCRPC: IsatuximabNSCLC: Isatuximab
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab291 ± 67.9280 ± 54.5
SecondaryPharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of REGN2810

Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for REGN2810 for participants with mCRPC and NSCLC.

Time frame:
At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · milligrams per liter
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of REGN2810
milligrams per litermCRPC: REGN2810NSCLC: REGN2810
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of REGN2810102 ± 26.1116 ± 21.4
SecondaryPharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours (AUC0-168 hr) After the First Administration of Isatuximab

AUC0-168 hr was defined as the area under the plasma concentration-time curve from time zero to 168h and was calculated using the trapezoidal method over the dosing interval (i.e., 7 days) for isatuximab alone.

Time frame:
At SOI, before actual EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · micrograms*hour per milliliter
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours (AUC0-168 hr) After the First Administration of Isatuximab
micrograms*hour per millilitermCRPC: IsatuximabNSCLC: Isatuximab
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours (AUC0-168 hr) After the First Administration of Isatuximab28400 ± 661024500 ± 5510
SecondaryPharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 504 Hours (AUC0-504 hr) After the First Administration of REGN2810

AUC0-504 hr was defined as the area under the plasma concentration-time curve from time zero to 504h and was calculated using the trapezoidal method over the dosing interval (i.e., 21 days) for REGN2810 alone.

Time frame:
At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, 336 hours and 504 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · milligrams*day per liter
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 504 Hours (AUC0-504 hr) After the First Administration of REGN2810
milligrams*day per litermCRPC: REGN2810NSCLC: REGN2810
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 504 Hours (AUC0-504 hr) After the First Administration of REGN2810903 ± 2571020 ± 229
SecondaryBest Percent-change From Baseline in Tumor Burden

Tumor burden change was defined as the best percent-change from Baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.

Time frame:
Up to 2 years
Reported as:
Mean · percent change
Best Percent-change From Baseline in Tumor Burden
percent changemCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Best Percent-change From Baseline in Tumor Burden12.9 ± 47.60.7 ± 10.1
SecondaryDuration of Response (DOR)

DOR: defined as time (in months) from date of first response (PR or CR in radiographic objective response, or PSA decline \>=50% for participants with mCRPC) that was subsequently confirmed to the date of first disease progression (PD) or death, whichever occurred first. PD included radiographic disease progression or unequivocal clinical progression. RECIST 1.1 criteria was used to assess radiographic PD in participants with NSCLC and PCWG3 criteria for participants with mCRPC. Per RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to \<10 mm and PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (Baseline sum if that was smallest), sum with an absolute increase of at least 5 mm and appearance of 1 or more new lesions.

Time frame:
From the date of first response until disease progression or death, whichever occurred first (maximum duration: up to 2 years)
Reported as:
Mean · months
Duration of Response (DOR)
monthsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Duration of Response (DOR)4.17—
SecondaryProgression-free Survival (PFS)

For mCRPC participants, PFS was defined as the time (in months) from first study treatment administration to the date of first documented disease progression or the date of death from any cause, whichever occurred first. Disease progression included radiographic disease progression (per PCWG3 criteria) or unequivocal clinical progression. For NSCLC participants, PFS was defined as the time from first study treatment administration to the date of first documented radiographic progression (PD) (per RECIST 1.1) or the date of death from any cause, whichever occurred first. Per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the Baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered as progression. Analysis was performed using Kaplan-Meier method.

Time frame:
From the date of the first study treatment administration to the date of first documented disease progression or death of any cause, whichever occurred first (maximum duration: up to 2 years)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Progression-free Survival (PFS)2.30 (1.906 to 4.271)4.01 (1.938 to 4.074)
SecondaryPercentage of Participants With Disease Control (DC) >=6 Months

Disease control: defined as percentage of participants with confirmed CR/PR/stable disease (SD), as assessed by Investigator PCWG3 modified RECIST 1.1 criteria relative to total number of participants in analysis population. Per PCWG3 modified RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to \<10 mm, PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference Baseline sum diameters and SD: neither sufficient shrinkage from the Baseline to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study, sum with an absolute increase of diameter of at least 5 mm and appearance of 1 or more new lesions.

Time frame:
From the date of first response to the date of first documented disease progression or death (due to any cause) (maximum duration: up to 2 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control (DC) >=6 Months
percentage of participantsmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Percentage of Participants With Disease Control (DC) >=6 Months20.8 (8.6 to 38.9)—

Adverse events

Collected over From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mCRPC: Isatuximab + REGN28102/24 (8.3%)11/24 (45.8%)24/24 (100%)
NSCLC: Isatuximab + REGN28102/20 (10%)14/20 (70%)19/20 (95%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
PneumoniaInfections and infestations0/242/20
DyspnoeaRespiratory, thoracic and mediastinal disorders0/242/20
Infusion Related ReactionInjury, poisoning and procedural complications2/241/20
Immune-Mediated EnterocolitisGastrointestinal disorders0/241/20
Intestinal ObstructionGastrointestinal disorders0/241/20
Malignant DysphagiaGastrointestinal disorders0/241/20
Disease ProgressionGeneral disorders0/241/20
Post Procedural HaematomaInjury, poisoning and procedural complications0/241/20
Cancer PainNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/241/20
Metastases To PeritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/241/20
Most frequent other events
Showing 10 of 34
Most frequent other events
EventmCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810
Infusion Related ReactionInjury, poisoning and procedural complications10/248/20
Decreased AppetiteMetabolism and nutrition disorders9/241/20
FatigueGeneral disorders8/243/20
CoughRespiratory, thoracic and mediastinal disorders4/246/20
Back PainMusculoskeletal and connective tissue disorders7/241/20
AstheniaGeneral disorders6/244/20
PyrexiaGeneral disorders6/244/20
DiarrhoeaGastrointestinal disorders5/242/20
Oedema PeripheralGeneral disorders5/240/20
NauseaGastrointestinal disorders4/243/20

Baseline characteristics

Analysis was performed on all-treated population which included all participants who signed the study informed consent (IC) and received at least 1 dose (even incomplete) of the study treatments, either isatuximab or REGN2810.

Age, Continuous
Age, Continuous(years)mCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810Total Title
Mean70.7 ± 6.565.4 ± 5.868.3 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)mCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810Total Title
Female066
Male241438
Race (NIH/OMB)
Race (NIH/OMB)(Participants)mCRPC: Isatuximab + REGN2810NSCLC: Isatuximab + REGN2810Total Title
American Indian or Alaska Native000
Asian6511
Native Hawaiian or Other Pacific Islander000
Black or African American011
White181028
More than one race000
Unknown or Not Reported044
08

Study locations

16 sites
  • Investigational Site Number 8400003
    Birmingham, Alabama 35249, United States
  • Investigational Site Number 8400007
    Atlanta, Georgia 30322, United States
  • Investigational Site Number 8400002
    Hackensack, New Jersey 07601, United States
  • Investigational Site Number 8400005
    Nashville, Tennessee 37203, United States
  • Investigational Site Number 8400004
    Houston, Texas 77030, United States
  • Investigational Site Number 2500002
    Bordeaux Cedex, 33076, France
  • Investigational Site Number 2500001
    Villejuif, 94800, France
  • Investigational Site Number 3800003
    Rozzano, Milano 20089, Italy
  • Investigational Site Number 3800001
    Orbassano, Torino 10043, Italy
  • Investigational Site Number 3800006
    Napoli, 80131, Italy
  • Investigational Site Number 3800004
    Padova, 35128, Italy
  • Investigational Site Number 3800005
    Verona, 37134, Italy
  • Investigational Site Number 1580002
    Tainan, 704, Taiwan
  • Investigational Site Number 1580001
    Taipei 100, Taiwan
  • Investigational Site Number 8260001
    Sutton, Surrey SM2 5PT, United Kingdom
  • Investigational Site Number 8260002
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Zucali PA, Lin CC, Carthon BC, Bauer TM, Tucci M, Italiano A, Iacovelli R, Su WC, Massard C, Saleh M, Daniele G, Greystoke A, Gutierrez M, Pant S, Shen YC, Perrino M, Meng R, Abbadessa G, Lee H, Dong Y, Chiron M, Wang R, Loumagne L, Lepine L, de Bono J. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697. PubMed 35058326 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Mar 2021, 38 months.

Results were first posted in May 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2017
First posted
Dec 11, 2017
StartActual
Jan 4, 2018
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 10, 2021
Results first posted
May 16, 2022
Last update
May 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03367819
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 11, 2017
Start date
Jan 4, 2018
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Results posted
May 16, 2022
Last update
May 16, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion